Figure 7. Internal validation of a MAPK-related signature in test2 cohort. (A) The distinguishment of high- and low-risk subgroups based on the median risk score in train cohort. (B) The distributions of the risk score and survival status. (C) Survival analysis in test2 cohort. (D) ROC curves of 1-, 3-, and 5-year survival. (E) Assessment of TME by “ESTIMATE”. (F) The discrepancies of immune response in high- and low-risk subgroups. (G) The discrepancies of ICD expression in high- and low-risk subgroups.